<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 174 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page173.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=174">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 174 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 174</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=174"><img src="../thumb/174.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Blood and Haemopoeitic - 8.3 / 8.4                                             2020-04 / 141
       case of allerg. reacts./sev.haemorrh.complicat., consid. haemorrh.as   Contraindications: Other salicylate hypersens., hist.of asthma   strong/mod. CYP2C19 inhibits.not recomm., discont.7 days prior to
       poss.cause of unusual sympts.dur. admin.  induc.by salicylates/ subst.with simil.act.notably NSAIDs, ac.GI   surg. if antiplatel.eff.not desir., spinal/epidur. anaesthet./lumb.punct.
       Drug interactions: Incr.haemorrh.risk wih curr./ prev. anticoags./  ulc., haemorrhag. diathes., sev.ren./hepat.impairm., sev.card.fail.,   dur.treatm./7 days thereaft., incr.bleed.risk, pts.to be aware that
       drugs which inhib.platel.format./ funct.  combinat.with methotrexate dos.of 15 mg/wk or more., last tri-  bleed. may take long.than usual to stop & to advise medic.practit.
                                     mest.of pregn.               accord., not init.with.first few days aft.MI, not recomm.in unstab.
                                     Side effects: Precipitat.brochosp., upper & low. GI disords./pain./  ang./PTCA (stent.)/CABG/ac.ischaem.stroke as lack of data, safety
       8.4    Platelet aggregation    inflammat./ulc.or haemorrh. & perforat., incr.bleed.risk incl.GI/cer-  of concom.heparin/other thrombolyt.agents not est., incr.bleed.risk
                                     ebral haemorrh. esp. in pts.with uncontr.hypertens./concom. anti-
                                                                  from dent./surg.proced./or other condits./ disords.requir.concom.
              inhibitors             haemostat. agents, ac.& chron.post haemorrhag. anaem./Fe.defic.  glycoprot. IIb/IIIa inhibit.
                                                                  Drug interactions: Potent.GI bleed.risk with NSAID’s incl COX-2
                                     anaem., hypersens. reacts. incl.asthma syndr./skin reacts./oed./
                                     rhinit. /nasal congest./cardio-resp.distress,& anaphylact. shock.,   inhibits./aspir., poss.incr.lev.of drugs metabol. by CYP2C9 enzyme.
       AGGRASTET, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  trans.hepat.impairm.  CLOPIDOGREL UNICORN 75 mg, Unicorn [P/S]
       Tirofiban HCl monohydr.       Special precautions: Hypersens.to analages./ anti-inflam.agents/  Clopidogrel
       Indications: In combinat.with heparin to prev. card. ischaem.events   antirheum.meds.& in pres.of other allergies., GI ulc.hist.incl.chron./  Indications: Reduct.of atherosclerot.events in pts. with hist.of symp-
       in pts.with unstab.ang.or non-Q-wave MI, coron.ischaem.syndr. un-  recurr.ulc. dis./ GI bleed.hist., concom.anticoags., imp.ren./ hepat.   tomat.atherosclerot.dis. defin. by MI from a few days until &lt;35 days/
       dergo. coron. angioplasty or atherectomy to prev.card. ischaem. com-  funct., concom.ibuprofen poss.limit cardioprotect. effs.in pts.with incr.  ischaem. stroke from 7 days until &lt;6 mnths.or est. periph.arter.dis.
       plicat.relat.to abrupt.clos.of treat. coron.artery.  CV risk., pre-exist. asthma/hayfev./nasal polyps/chron.resp. dis., incr.  (S3) TABS, 42/8.2/0250
       (S4) SOL FOR INFUS. 34/8.2/0481  bleed.tend.dur.& aft.surg., poss.trig.gout att. in predispos.pts.due to   722438-001: 75 mg, 30, R193,15
       701278-001: 0,05 mg/ml, 1x 250 ml pre-mix bag, R3 337,43  reduc.uric acid excret., poss. Reye’s syndr.partic.in childr.& adolesc.  Dosage: 75 mg as sngl.dly.dos.
                                                            nd
                                                          st
       Dosage: For IV use only. Avoid prolong.load.infus. Take care in calc.  with vir. infect.with/without fev, not recomm.dur.1  & 2  trimest.of   Contraindications: Act.bleed., safety & effic.in pts.&lt;18 yrs./pregn.
       bolus dos.& infus.rate bas.on pts.weight.  pregn., pass.into breastmilk, discont. breastfeed.if reg.use indicat.  & lactat.not est., sev.liv. impairm., thrombocytopen., platel.dysfunct.
       Unstab.ang.or Non-Q Wave MI: Admin.in combinat. with hepa-  Drug interactions: Irrevers.platel.inhibit. antagon. by ibuprofen,   Side effects: Thrombot.thrombocytopen.purpura (TTP), haematoma,
       rin. Init.infus.rate: 0,4 µg/kg/ min.for 30 min., cont.at a maint.dos.of   methotrex.ren.clear.decr. lead. to incr.haematolog.toxic., incr.bleed.  epistax., GI/IC haemorrh., sev. neutropen./ thrombocytopen., aplast.
       0,1 µg/kg/ min. See lit.to calc.ml/hr.rate of infus. for bolus & maint.   risk with thrombolytics/anticoags.& other inhibit.of platel. aggre-  anaem., pancytopen., bruis., haematur., ocul./resp.tract/ musculo-
       Infus.can be contin.through angiography & should be contin.for 12-  gat./ haemostas., incr.GI ulc./bleed.risk with NSAID’s & SSRI’s, digox.  skelet. bleed., aplast.anaem., haemorrh. ulc., haemothorax, operat.
       24 hrs.post angioplasty/ atherectomy.  plasma conc.incr., incr. hypoglycaem. eff.of antidiabet., diuret.decr.   wound & retroperiton. haemorrh., ser.sickn., GI disturbs., skin reacts.
       Angioplasty/atherectomy: Admin.in combinat. with heparin as   glomerul. filtrat., bld.lev.decr.by system. glucocortic., ACE inhibit.an-  incl. erythema multiforme/Stev.-John.syndr.& tox. epiderm. necrolys./
       an init.bolus of 10 µg/kg over 3 min.foll.by a maint.infus.rate of 0,15   tihypertens.eff.decr., incr. toxic.of valproic acid, alcoh.prolongs bleed.   lichen planus, headache, dizzin., paraesthes., vertigo, syncope, CNS
                                     time & incr.damage to GI mucosa, decr.uricosuric. eff.
       µg/kg/min., admin.maint.infus.for 36 hrs. See lit.to calc.ml/hr. rate   effs., taste disords., atr.fibrillat., palpitat., oed., vasculit., hyper-/hypo-
       of infus.for bolus & maint.   BRILINTA, AstraZeneca [P/S]  tens., URTI, bronchit., dyspn., cough, interstit.pneumonit., abnorm.LFT,
       Contraindications: Act.intern.bleed./hist.of diathes. bleed.within   Ticagrelor  hepatit., ac. liv.fail., UTI, glomerulopathy, arthralg., back/ gener./chest
       30 days, hist.of intracran. haemorrh./ neoplasm, arterioven. malfor-  Indications: Prevent.of thrombot.events in pts. with ac.coron.  pain, gout, leg cramps, arthrit., myalg., flu-like sympt., fatig., asthen.,
       mat./ aneurysm., hist of thrombocytopen. foll. prior expos., maj.surg./  syndr.incl.those manag.medic.& with percutan.coron. intervent./  oed., itch., tooth disords., hypersens.reacts.incl. bronchosp./ angioed.
       trauma (within prev.mnth.), CVA hist.within 30 days or any haemmor-  coron.art.by-pass graft.  Warnings and special precautions: Warn.pts. of TTP S&S, dis-
       rhag.stroke hist., hist./sympts./find. suggest.of aort.dissect., sev.hy-  (S3) TABS, 44/8.2/1041  cont.ther.if TTP susp., dent.& surg. proced., incr.act.bleed.risk, concom.
       pertens., ac pericardit., concom.use of other parenter.GP llb/ llla, rec.  720214-001: 90 mg, 56, R626,46  meds.incr. bleed. risk eg.anticoags./NSAID’s/COX-2 inhibits./ glyco-
       epidur.proced., chron.haemodialys., prolong. INR, safety in pregn.&   Dosage: Init.with sngl.180 mg load.dos.& cont.at 90 mg 2x dly.   prot. IIb & IIIa inhibit., safety with chron. concom. aspir./hepar./other
       lactat./when used in combin.with thrombolyt.agents not est., safety   Admin.with aspir. unless spec.C/I. Init.aspir.dos.to be follow.by   thrombolyt.agents/ warfar. not est., monit.for bleed.signs incl.occult
       & effic.in childr.not est.    75 -150 mg maint. dos. dly. Miss. dos: Admin.one 90 mg tab.at sched.   bleed. esp.dur.first ther.wks.&/aft.invas.card. surg./ proced., discont.7
       Side effects: Incr.in minor & maj.bleed.events. incl.intracran./ret-  time. Switch.pts.from clopidogrel to Brilinta: admin. 1  90 mg Brilin-  days prior to elect.surg.if antiplatel. eff.not desir., pts.with les.with
                                                           st
       roperiton.bleed., decr.platelet count, naus., fev.& headache, chills,   ta dos.24 hrs.follow.last clopidogrel dos. Ther.recomm.for at least   propensity to bleed/concom.meds.which poss. induce les., bleed.may
       hypersens. reacts.            12 mnths .unless discont.clinic.indicat.  take long.than usual to stop, pts.to report unusual bleed.& advise oth-
       Special precautions: Sev.ren.insuffic., platel. count &lt; 150 000   Contraindications: Act.patholog.bleed., inherit. bleed.disords.,   er medic. practit.accord., concom.aspir.in rec. TIA/ stroke, first few
           3
       cells/mm & haemorrhag. retinopathy, concom.meds.that inhib.hae-  sev.hepat. impairm., IC haemorrh. hist., strong CYP3A4 inhibits./  days aft.MI, not recomm.in CABG & ac.ischaem.stroke ie.less than
       mostas., monit.potent.bleed., discont.immed.if bleed. uncontroll.with   induc., safety in pregn./concom.warfar. not est., safety & effic.in   7 days, lact.intol., concom. omeprazole/ esomeprazole not recomm.
       press., females, elderly, see lit.for recomm.bleed.precaut.regard.  childr.bel.18 yrs.not est., no data avail.for treatm. long.than 12 mnths.  Drug interactions: Eff.of acetylsalic.acid on collag. induc.platelet
       the arterial access site & femor.sheath insert., see lit.for gen.nurs.   Side effects: Hyperuricaem., confus., headache, dizzin., IC/eye   aggregat.potent., incr. bleed. risk with heparin/aspir./warfarin/throm-
       guidelin., monit.platel.count/haemoglob.prior to treatm.& 6 hrs.aft.  haemorrh., paraesthes., vertigo, epistax., dyspn., haemoptys.,   bolyt., poss. incr.lev.of drugs metabol.by CYP2C9 enzyme, decr. anti-
       bolus infus.& daily to excl. thrombocytopen.& if verif.discont.immed.,   GI disords.incl. retroperiton. haemorrh., skin disords.incl.subcut.   platel.activ.with concom.omeprazole/ esomeprazole.
       monit. anticoag.effs.of heparin & adjust dos.accord. Do not admin.in   bleed., haemarthros., urin.tract bleed., post proced. haemorrh.,
       same IV line as diazepam.     other bleed.events.          CLOPIWIN 75, Winthrop [P/S]
       Drug interactions: Concom.heparin & aspirin assoc. with an incr.  Special precautions: Not studied in mod.hepat. impairm., not   Clopidogrel
       in bleed.time.                recomm.dur.breastfeed., avoid laps. in ther., incr.card.events risk if   Indications: Reduct.of atherothrombot.events as follows:
                                                                  Rec.MI/stroke/est.periph.arter.dis: Reduct.of atherothrombot.
       ASPIRIN TEVA 80, (Cipla) Teva [P/S]  ther.discont.requir., incr. CV death risk/MI due to underly.dis.in case of   events (MI/stroke/death due to vasc.causes).in pts. with hist.of symp-
                                     prem. discont.with any antiplatel.ther., pts.with bleed. propens., con-
       Acetylsalicylic acid (aspirin)  com.meds.poss.incr.bleed. risk/ NSAID’s/oral anticoags./& fibrinolyt.  tomat. atherosclerot.dis.defin.by ischaem.stroke from 7 days until &lt;6
       Indications: Reduc.MI risk in pts.with unstab. angina/ pts.who have   within 24 hrs. of dos., no exist.data regard.haemostat. benef. of platel.  mnths, MI from a few days until &lt;35 days or est.periph.arter. dis.
       had prev.MI, reduc.risk of recurr. trans.ischaem. attacks/stroke in men   transfus., discont.ther.5 days bef. elect. surg.if antiplatel.eff.not desir.,   Ac.coron.syndr: For pts.with non-ST segm.elev. ac.coron.syndr.(un-
       who have had trans.brain ischaem.due to fibrin.platelet emboli, reduc.  poss.discont. ther. if new/prolong./worsen.dyspn.devel.dur. treatm.,   stab.angina/non-Q-wave MI) incl.pts.to be manag.medic./those to be
       risk of graft occlus.follow.aorta coron. by-pass surg.  concom.high maint. aspir.dos.(300 mg) /concom. simvastat./lovastat.  manag. with percutan.coron.intervent.with/without stent or CABG:
       (S2) DISP.TABS. A38/8/0375    dos.&gt;40 mg not recomm., incr.bleed.risk e.g.dur.spin./epidur. anaes-  in combin.with ASA decr.rate of a combin. endpoint of CV death/
       712608-001: 80 mg, 30, R26,17  thes./ lumb.punct., neurolog.monit.for neuroax.haematoma recomm.  MI/stroke as well as the rate of a combin.endpoint of CV death/MI/
                st
       Dosage: 2 tabs on 1  day follow.by 1 tab.dly.pref. at same time dly.  dur.peri/post-op per., incr. bradycard.events risk, appropr.monit.with   stroke/refract.ischaem., in combin.with ASA reduc. death rate from
       Contraindications: Pept.ulc., haemophil., aspir. hypersens., sev.  concom. narrow therap.index P-gp depend.meds. incl. digox.  any cause & rate of combin. endpoint of death/ re-infarct./stroke in
       ren.imairm., concom.oral anticoag. ther., first & last trimest.of   Drug interactions: Incr.digox./simvastat./ atorvastat. AUC & C max,   pts.with ST-segm.elev.ac.MI
       pregn., lactat.               incr. AUC & C max with ketoconazole/diltiazem, decr.AUC & C max with   (S3) TABS, A41/8.2/0051
       Side effects: GI disords.incl.haemorrh., dizzin., incr. bleed.time,   rifampicin & other CYP3A4 induc.  711440-001: 75 mg, 28, R217,77
       bld.dyscras., iron-defic.anaem., ren. papill.necros., hypersens.  711440-002: 75 mg, 30, R233,34
       incl.angioed.                 CLOPIDOGREL 75 BIOTECH, Biotech [P/S]  Dosage: Rec.MI/stroke/est.periph.art.dis: 75 mg once dly.
       Warnings and special precautions: Reye’s syndr., concom.other   Clopidogrel  Ac.coron.syndr: Pts.with non-ST-segm.elevat. ac. coron.syndr.(un-
       gastr.irrit., imp.ren.funct., dyspeps., anaem., dehydrat., allerg.reacts.  Indications: Reduct.of atherosclerot.events in pts. with hist.of symp-  stable angina/non-Q-wave MI): Init.with sngl. 300 mg load.dos.&
       esp.in asthmat., bld.dyscras./Fe-defic.anaem./GI haemorrh./ pept.ul-  tomat. atherosclerot.dis. defin. by ischaem.stroke from 7 days until.   cont.at 75 mg once dly. Aspir.75-325 mg once dly.to be giv. in com-
       cer./ren.papill.necros., with prolong. use/high dos., withdr.1 wk bef.  &lt;6 mnths, MI from a few days until &lt;35 days or est. periph.arter.dis.  bin. Pts.with ST-segm.elevat. ac.MI: Recomm. dos.is 75 mg once
       surg., lact. intol., concom.corticoster.with high dos.longt. salicylate   (S3) TABS, 45/8.4/0327  dly admin.in combin.with aspir. with/without thrombolyt. May be
       ther., not to be used for platel.aggregat. inhibit. unless medic.direct.  721968-001: 75 mg, 28, R172,03  init.with/without a load.dos.
       Interactions: Coumar.anticoags./methotrexate/ sulphonur./hy-  Dosage: 75 mg as sngl.dly.dos.  Contraindications: Act.patholog.bleed., safety & effic.in chil-
       poglycaem./zafirlukast/phenytoin/ valproate activ.enhanc., reduc.  Contraindications: Act.bleed., safety & effic.in childr.&lt;18 yrs.not   dr.&lt;18 yrs/pregn. & lactat.not est., sev.liv.impairm., thrombocyto-
       eff.of cert.uricosur., incr.adverse eff.risk with other NSAIDs/alcoh.,   est., safety & effic.in pregn.& lactat. not est., sev.liv.impairm., throm-  pen., platel.dysfunct.
       poss. incr.excret.with corticoster., GI bleed./ulcer. risk incr.with   bocytopen., neutropen., other haematopoiet./haemorrh. disords.  Side effects: Thrombot.thrombocytopen.purpura (TTP), bleed.time
       corticoster., incr.excret.in alkal.urine with antacids, poss.enhanc.  Side effects: Thrombot. purpura (TTP), act.bleed. incl.IC haem-  prolong., bld.dyscras., neutropen. somet.sev., GI/IC/eye/nose/skin/
       salicylate toxic./resp. sympt.of salicylate overdos.poss.mask.with   orrh., leucopen., thrombocytopen., eosinopil., hypertens., haema-  musculoskelet./ resp.tract bleed.& at arter.punct.sites,, headache, diz-
       barbits./ other sedativ.      toma, eye bleed., agranulocytos., pancytopen., agranulocytopen.,   zin., paraesthes., vertigo, haematoma, GI disturbs., bruis., skin reacts.
                                     anaem., aplast.anaem., hypersens.reacts.incl. bronchsp./angioed.,
                                                                  incl.erythema multiforme /Stev.John.syndr./tox.epiderm. necrolys./
       BAYER ASPIRIN CARDIO 100, Bayer Consum. [P/S]  psych.disords, CNS effs., headache, dizzin., vertigo, taste disturbs.,   lichen planus, haematur., operat.wound haemorrh., bleed.with fatal
       Acetylsalicylic acid          insomn., paraesthes., atrial fibrillat., palpitat., oed., vasculit., hypo-  outcome, retroperiton. haemorrh., anaphylact.reacts, ser.sickn., CNS
       Indications: Reduc.MI risk in pts.with unstab. angina/pts.who have   tens., chest/back pain, upper.resp. infect., epistax., resp.tract bleed.,   effs., hallucinat., taste disords., vasculit., hypotens., bronchosp., in-
       had prev.MI, reduc.risk of recurr.trans.ischaem.attacks/stroke in men   bronchit., dyspn., cough, rhinit., GI disturbs., retroperiton. haemorrh.   terstit.pneumonit., colit., pancreatit., stomatit., abnorm.liv.funct.tests,
       who have had trans.brain ischaem.due to fibrin. platelet emboli, reduc.  incl.fatal outcome, pancreatit., colit., stomatit., abnorm.liv.funct.tests,   hepatit., ac.liv. fail., arthrit., arthralg., myalg., glomerulonephrit., when
       risk of graft occlus.follow. aorta coron.by-pass surg., reduc.myocard.   hepatit., ac. liv. fail., purpura, bruis., sev.skin reacts.incl.blister./ flak./  fev./other signs of infect.demonstr.consid. events relat.to myelotoxic.
       ischaem. event risk in presc.of CV risk fact.  peel., tox.epiderm.necrolys., Stev.Johns. syndr., lichen planus, gout,   Special precautions: Pts.to be advis.of TTP S&S, not recomm.in
       (S0) TABS. 31/8/0413          arthralg., haemarthros., arthrit., myalg., haematur., UTI, glomerulo-  ac.ischaem.stroke (less than 7 days), spinal/epidur.anaesthet./lumb.
       862304-008: 100 mg, 30, R40,49  nephrit., admin.site condits., syncope, tooth disord., flu-like sympt.,   punct.dur. treatm./7 days thereaft., discont.7 days prior to elect.surg.
       Dosage: Swall.whole. Do not chew/crush.  fev., asthen., fatig., bleed.time prolong., irrevers. platel.aggregat.  if antiplatel.eff.not desir, concom.ASA/ heparin /thrombolyt.agents/
       100-300 mg dly, pref.at same time dly.  inhibit.for 7-10 days.  NSAIDs incl.COX-2 inhibits./glycoprot.IIb/IIIa inhibit., incr.bleed.risk
       Reduc.myocard.ischaem.events in CV risk pts: 100 mg dly.,   Warnings and special precautions: Pts.to be advis.of TTP S&S,   with warfar., concom.strong/mod.CYP2C19 inhib. (eg.omeprazole &
       pref.at same time dly.        discont.if TTP susp., concom. other meds.incr.bleed.risk, concom.  esomeprazole) not recomm., pts. to be aware that bleed.may take</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page173.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page169.html">169</a>&nbsp;&nbsp;&nbsp;<a href="page170.html">170</a>&nbsp;&nbsp;&nbsp;<a href="page171.html">171</a>&nbsp;&nbsp;&nbsp;<a href="page172.html">172</a>&nbsp;&nbsp;&nbsp;<a href="page173.html">173</a>&nbsp;&nbsp;&nbsp;<a href="page174.html">174</a>&nbsp;&nbsp;&nbsp;<a href="page175.html">175</a>&nbsp;&nbsp;&nbsp;<a href="page176.html">176</a>&nbsp;&nbsp;&nbsp;<a href="page177.html">177</a>&nbsp;&nbsp;&nbsp;<a href="page178.html">178</a>&nbsp;&nbsp;&nbsp;<a href="page179.html">179</a>
             </td>
             <td width="35%"><a href="page175.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page175.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
